Glaukos Q4 Net Sales Surge 36% to $143.1M, 2026 Revenue Guide at 24%
Glaukos reported Q4 net sales of $143.1 million, up 36% year-over-year (34% constant currency), with U.S. glaucoma franchise sales surging 57% to $80.8 million on strong iDose adoption. It raised full-year 2025 net sales guidance to 28–29%, issued preliminary 2026 revenue guidance of 24% and won FDA approval for Epioxa.
1. Q4 Results and Growth
Glaukos reported consolidated net sales of $143.1 million in Q4 2025, a 36% increase on a reported basis and 34% constant currency. The U.S. glaucoma franchise led growth with $80.8 million in sales, up 57% year-over-year, driven by strong adoption of the iDose implant.
2. Upgraded Sales Guidance
Following the quarter, management raised full-year 2025 net sales guidance to 28%–29% growth and introduced preliminary revenue guidance for 2026 of 24%, reflecting confidence in continued franchise expansion and product rollouts.
3. FDA Approvals and Pipeline
The company secured FDA approval for Epioxa, its first incision-free keratoconus treatment, and is advancing iDose TRIO, a next-generation implant designed for in-office procedures, underpinning its long-term growth strategy.
4. Stock Performance and Market Impact
Glaukos shares have shown resilience despite a modest one-month decline of 3.22%, reflecting investor focus on robust top-line growth, expanded guidance and novel product approvals that could support sustained valuation gains.